Citigroup (C.US) accelerates promotion pace to counter private equity headhunting
Citi (C.US) is shortening the time required for investment banking analysts to be promoted to associates in order to attract and retain top talent in a highly competitive job market.
Zhitong Finance APP has learned that, according to reports, Citigroup (C.US) is shortening the time required for investment banking analysts to be promoted to managers (associates) in order to attract and retain top talent in an increasingly competitive job market. Currently, private equity firms are actively poaching junior bankers from Wall Street. According to an internal memo, this adjustment takes effect immediately, and Citigroup has also canceled fixed-term contracts for relevant employees in North America.
David Friedland, Co-Head of North America Investment Banking at Citigroup, said in an interview with Bloomberg on Monday (October 5) that Citigroup will shorten the analyst stage for junior investment banking employees from three years to two years, accelerating their promotion path and bringing Citigroup in line with some of its competitors. Under the new arrangement, current third-year analysts will, based on performance, be promoted to associates on January 1, 2027. The expected time for analysts to be promoted to Vice President (VP) has also been reduced from six and a half years to five and a half years.
This time, Citigroup has reduced the analyst phase to two years, which is even shorter than JPMorgan's two and a half years, indicating that banks are shifting from "tightening discipline" to "faster promotions" in order to compete for talent.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Bank of America gives Diodes a "Buy" rating, driving its stock price up
October 6 - Semiconductor product manufacturer Diodes (DIOD.O) saw its stock price rise 3.38% in pre-market trading to $107.64. BofA has initiated coverage of DIOD with a “Buy” rating and a price target of $135, implying about 30% upside from the previous closing price. According to the report, DIOD holds a favorable position in the automotive, industrial, and AI data center semiconductor markets, positioning it to expand its market share. The increasing use of semiconductors in automobiles and growing demand for AI infrastructure are expected to drive the company’s long-term growth. The firm anticipates that DIOD’s AI data center business—which currently accounts for about 12% of total revenue—could triple by 2030. As of the previous trading day’s close, the stock’s year-to-date growth has already more than doubled. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Automated translations may contain errors or lack context and are provided solely for the convenience of readers. Reuters accepts no liability for any damages or losses resulting from the use of automated translation features.)
BUZZ-BridgeBio shares rise as FDA initiates priority review for dwarfism drug
On October 6th, shares of pharmaceutical company BridgeBio Pharma (BBIO.O) rose 2.5% in pre-market trading to $67.80. The company announced that the U.S. Food and Drug Administration (FDA) has granted priority review to its application seeking approval for the investigational oral drug infigratinib for the treatment of children with achondroplasia, the most common type of dwarfism. The FDA has set a target decision date of February 4, 2027. The application is based on a late-stage clinical trial that met both primary and key secondary endpoints; children treated with infigratinib experienced an adjusted annual growth velocity 1.74 centimeters greater than those given placebo. The drug also improved arm span and body proportions in children under eight years old. No serious adverse events or discontinuations related to the drug were reported. BridgeBio plans to apply for European approval in the fourth quarter of 2026. As of the close of the previous trading day, BBIO shares are down 13.5% year-to-date. (For the convenience of non-English speakers, Reuters has automated this report into several other languages. Because automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of automated translation, which is provided for readers’ convenience only. Reuters accepts no liability for any damages or losses arising from the use of automated translation.)
Google (GOOGL.US) spends $4.3 billions on electricity, securing 3,590 megawatts of long-term energy from Constellation Energy (CEG.US).
Google has signed a 3,590 MW power purchase agreement with Constellation Energy, with a quarter of the electricity coming from nuclear power, involving an investment of $4.3 billion.
BUZZ - Torm shares decline as Oaktree exits in a $253.5 million secondary offering
Updated Pricing Details: On October 6th, before the market opened on Tuesday, shares of the tanker operator Torm (TRMD.O), listed in the US, dropped 3.2% to $39.72 after the company announced the pricing of its secondary offering. According to the company (link), funds managed by Oaktree Capital Management sold approximately 6.3 million shares, raising a total of about $253.5 million. The secondary offering was priced at $40.05 per share, a 2.4% discount to the stock's previous closing price. According to the prospectus, Oaktree Capital completely exited its remaining approximately 6.2% stake following the sale (link). JPMorgan served as the sole underwriter for this issuance. Last month, Oaktree Capital (link) sold shares in another secondary offering of 9 million shares at $32.25 per share. Driven by record freight rates, the shares of tankers listed in Northern Europe (link) have soared, and Torm's stock closed up 2.6% on Monday at $41.05. As of Monday’s close, the company’s US-listed shares had surged about 110% year-to-date, including a 47% gain over the past three months. (For the convenience of non-English speakers, Reuters provides its report with automated translation into several languages. Due to the possibility of errors or the lack of contextual accuracy from automated translation, Reuters does not guarantee the accuracy of these texts. The automated translation is provided for readers’ convenience only. Reuters accepts no liability for any damage or loss arising from the use of automated translation features.)
